IDEAYA Biosciences, Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>IDEAYA Biosciences, Inc. has filed its Definitive Proxy Statement (DEF 14A) on April 19, 2024, for the fiscal year ending May 31, 2024.</b>

AI Summary

IDEAYA Biosciences, Inc. (IDYA) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Filing type: DEF 14A (Definitive Proxy Statement). Filing date: 2024-04-19. Reporting period: Fiscal year ending 2024-05-31. Company SIC code: 2834 (Pharmaceutical Preparations). Incorporated in: Delaware.

Why It Matters

For investors and stakeholders tracking IDEAYA Biosciences, Inc., this filing contains several important signals. This filing is a standard proxy statement, indicating the company is preparing for shareholder meetings and votes, which are crucial for corporate governance and strategic decisions. The detailed breakdown of equity award valuations for 2021-2023 suggests a focus on executive compensation and shareholder value, a key area of interest for investors.

Risk Assessment

Risk Level: low — IDEAYA Biosciences, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, providing information on executive compensation and corporate governance, with no immediate financial or operational risks indicated.

Analyst Insight

Review the executive compensation details and any shareholder proposals within the proxy statement to understand potential impacts on company strategy and investor relations.

Key Numbers

• 2024-04-19 — Filing Date (DEF 14A)
• 2024-05-31 — Period of Report (DEF 14A)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 001-38915 — SEC File Number (DEF 14A)

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Filer
• 0000950170-24-045724 (filing_id) — Accession Number
• 2024-04-19 (date) — Filing Date
• 2024-05-31 (date) — Period of Report
• 2834 (sic_code) — Standard Industrial Classification
• DE (jurisdiction) — State of Incorporation
• 650-443-6209 (phone) — Business Phone
• 7000 SHORELINE COURT, SUITE 350 (address) — Business Address

FAQ

Industry Context

IDEAYA Biosciences, Inc. operates in the Pharmaceutical Preparations industry, focusing on the development of targeted cancer therapies.

Regulatory Implications

As a publicly traded company, IDEAYA Biosciences, Inc. is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings and votes.

What Investors Should Do

1. Analyze the executive compensation structure and any proposed changes.
2. Review shareholder proposals and voting recommendations.
3. Note any disclosures related to board of directors' composition and governance practices.

Key Dates

• 2024-04-19: Filing Date — Submission of Definitive Proxy Statement
• 2024-05-31: Fiscal Year End — Period covered by the proxy statement

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for public companies regarding shareholder meetings and executive compensation, rather than a financial results report.

Key Financial Figures

• $0.0001 — s of IDEAYA are shares of common stock, $0.0001 par value per share (the "common stock"

Filing Documents

• idya-20240418.htm (DEF 14A) — 998KB
• img42053973_0.jpg (GRAPHIC) — 81KB
• img42053973_1.jpg (GRAPHIC) — 68KB
• img42053973_2.jpg (GRAPHIC) — 78KB
• img42053973_3.jpg (GRAPHIC) — 1305KB
• img42053973_4.jpg (GRAPHIC) — 383KB
• 0000950170-24-045724.txt (&nbsp;) — 6059KB
• idya-20240418.xsd (EX-101.SCH) — 40KB
• idya-20240418_htm.xml (XML) — 211KB

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 33 Summary Compensation Table 33 Grants of Plan-Based Awards 34 Outstanding Equity Awards at Fiscal Year-End 35 Option Exercises and Stock Vested 35 Potential Payments Upon Termination or Change in Control 35 Pay Ratio of CEO to Median Employee 37 Pay Versus Performance 38 Equity Compensation Plan Information 42 INFORMATION ABOUT STOCK OWNERSHIP 43 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 45 ADDITIONAL INFORMATION 45 Householding of Proxy Materials 45 Other Matters 45 IDEAYA BIOSCIENCES, INC. 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS MAY 31, 2024 We have sent you this Proxy Statement and the enclosed Proxy Card because the Board of Directors (the "Board") of IDEAYA Biosciences, Inc. (referred to herein as the "Company", "IDEAYA", "we", "us" or "our") is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the "Annual Meeting") to be held on Friday, May 31, 2024, at 12:30 p.m. Pacific Time. The Annual Meeting will be held entirely online in order to provide expanded stockholder access and participation, as well as improved communications. You will be able to attend and participate in the Annual Meeting online by registering at www.proxydocs.com/IDYA . Once registered you will receive further instructions via email on how to listen to the meeting live, submit questions, and vote. This Proxy Statement summarizes information about the proposals to be considered at the Annual Meeting and other information you may find useful in determining how to vote. The Proxy Card is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and pers

View Full Filing

View this DEF 14A filing on SEC EDGAR